142 related articles for article (PubMed ID: 16815959)
1. CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody.
Zhu LR; Thomas PE; Lu G; Reuhl KR; Yang GY; Wang LD; Wang SL; Yang CS; He XY; Hong JY
Drug Metab Dispos; 2006 Oct; 34(10):1672-6. PubMed ID: 16815959
[TBL] [Abstract][Full Text] [Related]
2. The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL; He XY; Shen J; Wang JS; Hong JY
Toxicol Sci; 2006 Nov; 94(1):38-45. PubMed ID: 16917071
[TBL] [Abstract][Full Text] [Related]
3. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
4. Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: in vivo studies using a CYP2A13-humanized mouse model.
Megaraj V; Zhou X; Xie F; Liu Z; Yang W; Ding X
Carcinogenesis; 2014 Jan; 35(1):131-7. PubMed ID: 23917075
[TBL] [Abstract][Full Text] [Related]
5. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
6. Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract.
Chiang HC; Wang CK; Tsou TC
Respiration; 2012; 84(4):319-26. PubMed ID: 22890016
[TBL] [Abstract][Full Text] [Related]
7. CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline.
Fukami T; Nakajima M; Sakai H; Katoh M; Yokoi T
Drug Metab Dispos; 2007 Mar; 35(3):335-9. PubMed ID: 17178771
[TBL] [Abstract][Full Text] [Related]
8. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2A13 enhances the sensitivity of human bronchial epithelial cells to aflatoxin B1-induced DNA damage.
Yang X; Zhang Z; Wang X; Wang Y; Zhang X; Lu H; Wang SL
Toxicol Appl Pharmacol; 2013 Jul; 270(2):114-21. PubMed ID: 23602888
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation of human CYP2A13 expression in the respiratory tract by CCAAT/enhancer binding protein and epigenetic modulation.
Ling G; Wei Y; Ding X
Mol Pharmacol; 2007 Mar; 71(3):807-16. PubMed ID: 17148654
[TBL] [Abstract][Full Text] [Related]
11. Efficient activation of aflatoxin B1 by cytochrome P450 2A13, an enzyme predominantly expressed in human respiratory tract.
He XY; Tang L; Wang SL; Cai QS; Wang JS; Hong JY
Int J Cancer; 2006 Jun; 118(11):2665-71. PubMed ID: 16385575
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2A13 mediates the neoplastic transformation of human bronchial epithelial cells at a low concentration of aflatoxin B1.
Zhang Z; Lu H; Huan F; Meghan C; Yang X; Wang Y; Wang X; Wang X; Wang SL
Int J Cancer; 2014 Apr; 134(7):1539-48. PubMed ID: 24114584
[TBL] [Abstract][Full Text] [Related]
13. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach.
Chiang HC; Wang CY; Lee HL; Tsou TC
Toxicol Appl Pharmacol; 2011 Jun; 253(2):145-52. PubMed ID: 21473878
[TBL] [Abstract][Full Text] [Related]
15. Suppression of pulmonary CYP2A13 expression by carcinogen-induced lung tumorigenesis in a CYP2A13-humanized mouse model.
Liu Z; Megaraj V; Li L; Sell S; Hu J; Ding X
Drug Metab Dispos; 2015 May; 43(5):698-702. PubMed ID: 25710941
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2A13 mediates aflatoxin B1-induced cytotoxicity and apoptosis in human bronchial epithelial cells.
Yang XJ; Lu HY; Li ZY; Bian Q; Qiu LL; Li Z; Liu Q; Li J; Wang X; Wang SL
Toxicology; 2012 Oct; 300(3):138-48. PubMed ID: 22743290
[TBL] [Abstract][Full Text] [Related]
17. Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung.
Zhang X; Caggana M; Cutler TL; Ding X
J Pharmacol Exp Ther; 2004 Oct; 311(1):373-81. PubMed ID: 15175424
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers.
Fukami T; Nakajima M; Matsumoto I; Zen Y; Oda M; Yokoi T
Cancer Sci; 2010 Apr; 101(4):1024-8. PubMed ID: 20180810
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J; Zhang X; Wu H; Ling G; Wang S; Zhang QY; Liu F; Ding X
Drug Metab Dispos; 2008 Nov; 36(11):2316-23. PubMed ID: 18669584
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of nicotine and cotinine by human cytochrome P450 2A13.
Bao Z; He XY; Ding X; Prabhu S; Hong JY
Drug Metab Dispos; 2005 Feb; 33(2):258-61. PubMed ID: 15528319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
